前列腺床挽救性立体定向消融放疗后的毒性特征与患者报告结局:POPART多中心前瞻性研究
POPART多中心前瞻性研究纳入50例根治性前列腺切除术后PSA 0.1–2.0 ng/mL的患者,接受前列腺床五分割隔日Linac-based SABT总剂量32.5 Gy(EQD2₁.₅=74.3 Gy)。未发生≥G2晚期GI或GU毒性,晚期G1泌尿毒性和直肠毒性分别占46%和4%;47例完成EPIC-CP评估者中4例(9%)生活质量恶化,11例(26%)出现勃起功能障碍并与PTV D2%相关(P=0.032)。作者认为术后SBRT未增加毒性也未导致生活质量显著下降,可安全扩展至术后场景,但需长期随访和随机对照验证。
要点
- 50例根治性前列腺切除术后PSA 0.1–2.0 ng/mL患者接受前列腺床五分割SABT 32.5 Gy(EQD2₁.₅=74.3 Gy)。
- 未登记≥G2晚期GI或GU毒性,晚期G1泌尿毒性和直肠毒性分别占46%和4%。
- 47例完成EPIC-CP评估者中4例(9%)生活质量恶化,11例(26%)出现勃起功能障碍并与PTV D2%相关(P=0.032)。
核心结论
- 作者认为根治性前列腺切除术后SBRT未导致毒性增加,也未导致生活质量指标显著下降,因此可安全扩展至术后场景。
- 作者指出需长期随访以及与不同放疗方案的随机对照比较来验证该方法。
研究设计与样本
- POPART为多中心前瞻性研究,纳入根治性前列腺切除术后PSA 0.1–2.0 ng/mL的患者。
- 患者接受Linac-based前列腺床SBRT,五分割隔日照射,总剂量32.5 Gy(EQD2₁.₅=74.3 Gy)。
- 2021年4月至2023年4月共入组并治疗50例患者,中位随访12.2(3–27)个月。
- 晚期毒性采用CTCAE v.5评估,生活质量和生化控制采用EPIC-CP、ICIQ-SF、IIEF 5问卷及PSA水平评估。
- 治疗前后评分采用配对t检验比较,最小重要差值(MID)设定为大于基线合并标准差(pooled SD)的0.5倍。
主要发现
- 未登记≥G2晚期GI或GU毒性。
- 晚期G1泌尿毒性发生于46%的患者,晚期G1直肠毒性发生于4%的患者。
- 47例完成全部EPIC-CP域的患者中,4例(9%)生活质量恶化,11例(26%)出现勃起功能障碍,且与PTV D2%相关(P=0.032)。
- 多因素分析显示膀胱壁D10cc与晚期G1 GU毒性独立相关(P=0.034)。
- 治疗后PSA最低值中位数为0.04 ng/mL(0.00–0.84);末次随访时6例出现生化失败,其中2例为淋巴结复发。
局限性
- 作者指出需长期随访来验证该方法。
- 作者指出需与不同放疗方案进行随机对照比较来验证该方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While SBRT to the prostate has become a valuable option as a radical treatment, limited data support its use in the postoperative setting. Here, we report the updated results of the multicentric Post-Prostatectomy Ablative Radiation Therapy (POPART) trial, investigating possible predictors of toxicities and patient-reported outcomes. METHODS: Patients with PSA levels between 0.1-2.0 ng/mL after radical prostatectomy received Linac-based SBRT to the prostate bed in five fractions every other day for a total dose of 32.5 Gy (EQD21.5 = 74.3 Gy). Late toxicity was assessed using CTCAE v.5 scale, while EPIC-CP, ICIQ-SF, IIEF 5 questionnaires and PSA levels measured quality of life and biochemical control. Pre- and post-treatment scores were compared using a paired t-test, with MID established at > 0.5 pooled SD from the baseline. A logistic regression analysis was performed to evaluate potential associations between specific patient/tumor/treatment factors and outcome deterioration. RESULTS: From April 2021 to April 2023 a total of 50 pts were enrolled and treated. Median follow-up was 12.2 (3-27) months. No late ≥ G2 GI or GU toxicity was registered. Late G1 urinary and rectal toxicities occurred in 46 % and 4 % of patients, respectively. Among 47 patients completing all EPIC-CP domains, four (9 %) showed worsened QoL, and eleven (26 %) developed erectile dysfunction correlating with PTV D2% (P = 0.032). At Multivariate analysis bladder wall D10cc independently correlated with late G1 GU toxicity (P = 0.034). Median post-treatment PSA nadir was 0.04 ng/mL (0.00 - 0.84). At the last follow-up, six patients presented with biochemical failure, including two nodal relapses. CONCLUSIONS: Our findings show that post-prostatectomy SBRT did not result in increased toxicity nor a significant decline in QoL measures, thus showing that it can be safely extended to the postoperative setting. Long-term follow-up and randomized comparisons with different RT schedules are needed to validate this approach.
引用
- Ferrario F, Franzese C, Faccenda V, et al. Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study. Clin Transl Radiat Oncol. 2023. PMID: 38111610. doi:10.1016/j.ctro.2023.100704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。